NCT07165951 is a Phase 3 clinical trial of TQB2868 Injection in Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd..

Who is sponsoring NCT07165951?

NCT07165951 is sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd..

What drugs are being tested in NCT07165951?

Interventions in NCT07165951: TQB2868 Injection, Anlotinib Hydrochloride Capsules, Gemcitabine Hydrochloride Injection, Paclitaxel for Injection, TQB2868 Placebo.

What condition does NCT07165951 study?

NCT07165951 studies Metastatic Pancreatic Ductal Adenocarcinoma.

Is NCT07165951 still recruiting?

NCT07165951 is currently recruiting now. Last updated 28 May 2026.

Last reviewed 2026-05-28 · How we verify

NCT07165951

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-blind, Parallel-controlled, Multicenter Phase III Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules to Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Recruiting now Phase 3 Last updated 28 May 2026

What this trial tests

Phase 3 trial testing TQB2868 Injection in Metastatic Pancreatic Ductal Adenocarcinoma in 566 participants. Currently enrolling.

Timeline

2 December 2025

Primary endpoint
1 May 2028

1 December 2028

Quick facts

Lead sponsor	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	566
Start date	2 December 2025
Primary completion	1 May 2028
Estimated completion	1 December 2028
Sites	71 locations across China

Drugs / interventions tested

TQB2868 Injection — full drug profile →
Anlotinib Hydrochloride Capsules — full drug profile →
Gemcitabine Hydrochloride Injection — full drug profile →
Paclitaxel for Injection — full drug profile →
TQB2868 Placebo

Conditions studied

Metastatic Pancreatic Ductal Adenocarcinoma — all drugs for Metastatic Pancreatic Ductal Adenocarcinoma →

Sponsor

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Metastatic Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Overall Survival
Time frame: The duration is approximately 2 years
By evaluating overall survival (OS), this study aims to demonstrate the efficacy of TQB2868 injection combined with anlotinib hydrochloride capsules in chemotherapy compared to placebo combined with chemotherapy in the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).

Sponsor's own description

This study adopts a randomized, open label, placebo-controlled, multicenter trial design. OS was the primary endpoint, and eligible subjects were randomly divided into 1:1 groups and received TQB2868 injection and anlotinib hydrochloride capsules combined with chemotherapy, compared to placebo combined with chemotherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Metastatic Pancreatic Ductal Adenocarcinoma

Currently open trials in the same condition.

NCT06904378 — ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma · Phase 1, PHASE2 · recruiting
NCT07214298 — Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma · Phase 1, PHASE2 · recruiting
NCT07089940 — OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma · EARLY_PHASE1 · recruiting
NCT06989437 — A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Signif · Phase 2, PHASE3 · recruiting
NCT07096362 — Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma · Phase 2 · recruiting

Other Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. trials

Trials by the same sponsor.

NCT06760182 — Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07165951 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Last refreshed: 28 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07165951.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing